Summary of COVID-19 conestat alfa studies
Hide extended summaries
38 patient conestat alfa late treatment RCT: 78% lower mortality (p=0.29), 87% lower ventilation (p=0.08), 46% lower progression (p=0.07), and 52% shorter hospitalization (p=0.06).
RCT 38 hospitalized COVID-19 patients showing non-significant improvements with conestat alfa. Results of this manufacturer RCT are notably better than the non-manufacturer RCT [Urwyler].
Nov 2021, NCT04530136, https://clinicaltrials.gov/study/NCT04530136, https://c19p.org/bernstein
RCT 84 hospitalized COVID-19 patients showing higher mortality with conestat alfa (recombinant C1 inhibitor), without reaching statistical significance.
Oct 2023, Frontiers in Immunology, https://www.frontiersin.org/articles/10.3389/fimmu.2023.1255292/full, https://c19p.org/urwyler
38 patient conestat alfa late treatment RCT: 78% lower mortality (p=0.29), 87% lower ventilation (p=0.08), 46% lower progression (p=0.07), and 52% shorter hospitalization (p=0.06).
RCT 38 hospitalized COVID-19 patients showing non-significant improvements with conestat alfa. Results of this manufacturer RCT are notably better than the non-manufacturer RCT [Urwyler].
Nov 2021, NCT04530136, https://clinicaltrials.gov/study/NCT04530136, https://c19p.org/bernstein
2. Urwyler et al., Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial
83 patient conestat alfa late treatment RCT: 238% higher mortality (p=0.26), 286% higher ventilation (p=0.26), 141% higher ICU admission (p=0.32), and 117% lower hospital discharge (p=0.12).RCT 84 hospitalized COVID-19 patients showing higher mortality with conestat alfa (recombinant C1 inhibitor), without reaching statistical significance.
Oct 2023, Frontiers in Immunology, https://www.frontiersin.org/articles/10.3389/fimmu.2023.1255292/full, https://c19p.org/urwyler
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.